Please wait...
The relationship of dysphagia and electrolyte imbalance in ischemic stroke patients treated in the nerve ward of Arifin Achmad Hospital, Riau Province, 2023
University of Riau
Indonesia
Biography
Riki Sukiandra, MD, PhD, Neurologist was born in Pangkalan on December 20, 1978. He obtained his Medical Doctor degree from the Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, in 2003. He then completed his residency training in Neurology at Universitas Gadjah Mada, Yogyakarta, in 2008. In 2021, he earned his Doctorate in Biomedical Science from Universitas Andalas, Padang, and later pursued a fellowship in Neurointensive Care in 2023. He has been serving as a lecturer at the Department of Neurology, Faculty of Medicine, Universitas Riau, and a consultant neurologist at Arifin Ahmad General Hospital since 2008. In addition, he practices as a neurologist at Awal Bros Pekanbaru Hospital and Syafira Hospital Pekanbaru. Currently, he holds the position of Head of the Clinical Department at the Faculty of Medicine, Universitas Riau. He is an active member of the Indonesian Neurological Association (PERDOSNI), the Neurointensive Study Group, and the Pain Study Group. He has also served as Secretary and Head of the PERDOSNI Pekanbaru Chapter for multiple terms. His academic and clinical interests focus on neurointensive care, stroke, and neurological emergencies. He has over 10 publications.
DISCOVER
Speakers
Characteristic linguistic styles in young Arabic speaking children diagnosed with ASD
Alyn Hospital
Israel
Speakers
Investigating the cellular mechanisms underpinning the role of leptin and ghrelin and their receptors on hippocampal neurons
University of St Andrews
United Kingdom
Speakers
NRS-2002 scale impact on nutritional status screening of patients with acute cerebrovascular accident
Sechenov University
Russian Federation
Speakers
miRNA expression changes in PD blood leukocytes
UCL
UK
Riki Sukiandra presents at the Healthcore Bridge International Medical Conference 2026 — October 16, 2026, Hall B — Infectious Diseases & Immunology, Level 2.
FAQs
Prof. Tanaka will deliver an invited lecture titled 'Alzheimer's Therapeutics 2026: Translating Lecanemab Data to Clinical Reality' in the Neuroscience & Neurology track on Day 2. The presentation features 36-month real-world data from Japan and previews the next wave of anti-amyloid and anti-tau therapies.
Prof. Tanaka served as Asia-Pacific Principal Investigator for the CLARITY-AD Phase III trial of lecanemab. His team enrolled 342 participants across 18 sites in Japan and Korea, and biomarker data from his laboratory directly informed the patient selection criteria incorporated into approved prescribing guidance in Japan and the EU.
Prof. Tanaka's research supports blood-based p-tau217 as the primary screening and monitoring biomarker for anti-amyloid therapy. He also advocates for tau PET imaging at key decision points — particularly before treatment initiation and at 12 months — based on data from the CLARITY-J real-world registry.
Yes. Prof. Tanaka is Principal Investigator for two Phase III trials: one examining anti-tau monotherapy in early Alzheimer's, and one evaluating a dual anti-amyloid/anti-tau combination regimen. Both are currently enrolling across Japan, South Korea, and Singapore.
© 2026 Healthcore Bridge. All rights reserved. Advancing global healthcare through collaboration & innovation.